Tisdag 21 Januari | 22:56:39 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-15 08:00 Kvartalsrapport 2025-Q2
2025-05-08 N/A Årsstämma
2025-04-29 08:00 Kvartalsrapport 2025-Q1
2025-02-05 08:00 Bokslutskommuniké 2024
2024-12-11 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning SOBI 0.00 SEK
2024-05-14 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-10-30 - Kvartalsrapport 2023-Q3
2023-08-15 - Extra Bolagsstämma 2023
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-10 - X-dag ordinarie utdelning SOBI 0.00 SEK
2023-05-09 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-08 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning SOBI 0.00 SEK
2022-05-10 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-10 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-21 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning SOBI 0.00 SEK
2021-05-04 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning SOBI 0.00 SEK
2020-05-13 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-07-17 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning SOBI 0.00 SEK
2019-05-09 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-10-31 - Kvartalsrapport 2018-Q3
2018-07-18 - Kvartalsrapport 2018-Q2
2018-05-11 - X-dag ordinarie utdelning SOBI 0.00 SEK
2018-05-09 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-05 - X-dag ordinarie utdelning SOBI 0.00 SEK
2017-05-04 - Årsstämma
2017-04-28 - Kvartalsrapport 2017-Q1
2017-02-16 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-05-24 - Årsstämma
2016-05-20 - X-dag ordinarie utdelning SOBI 0.00 SEK
2016-04-27 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-07-17 - Kvartalsrapport 2015-Q2
2015-05-07 - X-dag ordinarie utdelning SOBI 0.00 SEK
2015-05-06 - Årsstämma
2015-05-06 - Kvartalsrapport 2015-Q1
2015-02-19 - Bokslutskommuniké 2014
2014-10-30 - Kvartalsrapport 2014-Q3
2014-10-30 - Analytiker möte 2014
2014-07-18 - Kvartalsrapport 2014-Q2
2014-05-09 - X-dag ordinarie utdelning SOBI 0.00 SEK
2014-05-08 - Årsstämma
2014-05-08 - Kvartalsrapport 2014-Q1
2014-02-20 - Bokslutskommuniké 2013
2013-11-05 - Kapitalmarknadsdag 2013
2013-11-05 - Analytiker möte 2013
2013-10-30 - Kvartalsrapport 2013-Q3
2013-07-18 - Kvartalsrapport 2013-Q2
2013-04-29 - X-dag ordinarie utdelning SOBI 0.00 SEK
2013-04-26 - Årsstämma
2013-04-26 - Kvartalsrapport 2013-Q1
2013-02-21 - Bokslutskommuniké 2012
2012-10-30 - Kvartalsrapport 2012-Q3
2012-10-30 - Analytiker möte 2012
2012-07-19 - Kvartalsrapport 2012-Q2
2012-04-27 - X-dag ordinarie utdelning SOBI 0.00 SEK
2012-04-26 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-02-23 - Bokslutskommuniké 2011
2011-11-29 - Kapitalmarknadsdag 2011
2011-10-20 - Kvartalsrapport 2011-Q3
2011-08-24 - Extra Bolagsstämma 2011
2011-07-19 - Kvartalsrapport 2011-Q2
2011-04-29 - X-dag ordinarie utdelning SOBI 0.00 SEK
2011-04-28 - Årsstämma
2011-04-20 - Kvartalsrapport 2011-Q1
2011-02-23 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-07-20 - Kvartalsrapport 2010-Q2
2010-04-28 - X-dag ordinarie utdelning SOBI 0.00 SEK
2010-04-27 - Kvartalsrapport 2010-Q1
2009-04-29 - X-dag ordinarie utdelning SOBI 0.00 SEK
2008-04-25 - X-dag ordinarie utdelning SOBI 0.00 SEK
2007-05-04 - X-dag ordinarie utdelning SOBI 0.00 SEK

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Swedish Orphan Biovitrum, även kända under namnet Sobi, är ett internationellt läkemedelsbolag. Störst inriktning återfinns inom tillhandahållandet av innovativa behandlingar och service för patienter med sällsynta sjukdomar. Produkterna som bolaget utvecklar fokuserar på inflammatoriska- samt genetiska sjukdomar. Sobi marknadsför även särskilda specialist- och sårläkemedel under olika varumärken. Huvudkontoret ligger i Stockholm.
2025-01-10 18:00:00

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2) was in the mid-30s per cent of revenues.

 

The main reasons for the increased revenue are higher sales than expected in Q4 across the Haemophilia portfolio and for Kineret.

  • Altuvoct: Higher than expected rate of new patients switching to Altuvoct in markets where the product has been launched, mainly Germany and Switzerland.
  • Elocta: Benefited from higher patient numbers across markets and in markets where Altuvoct is launched there were less switches than expected from Elocta. Favorable gross-to-net effects were also observed.
  • Alprolix: Higher than expected number of new patients as well as increase in on-demand treatments across Europe.
  • Kineret: Higher than expected sales driven mainly by positive gross-to-net adjustments and favorable order phasing but also supported by increased demand.
  • The adjusted EBITA margin remained in the expected range as the stronger revenue performance was offset by negative mix effects on the gross margin as well as investments into our launch and pipeline products in the fourth quarter.

 

At the publication of the Q3 2024 report on 24 October 2024 Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue.

 

Sobi will announce its fourth quarter and full year 2024 report on Wednesday 5 February 2025 at 8:00 am CET.

 

 

About Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

 

Contacts

 

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

 

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 18:00 CET on 10 January 2025.

 

 Gerard Tobin

 

Head of Investor Relations

[1] Alternative Performance Measures (APMs).

[2] Excluding items affecting comparability (IAC).